Biomarker NTRK Coverage from Every Angle

Alexander Drilon, MD, on Understanding the Structure of NTRK Fusions and Their Actionable Targets

Posted: Sunday, August 1, 2021

Alexander E. Drilon, MD, of Memorial Sloan Kettering Cancer Center, discusses the structure of NTRK fusions, which are similar to other gene rearrangements such as ROS1 and ALK-RET, as well as their upstream partners such as ETV6, which seems to be prevalent in secretory, breast, and salivary gland cancers, as well as congenital fibrous sarcoma.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.